Soluble antigens derived from Coxiella burnetii elicit protective immunity in three animal models without inducing hypersensitivity.

Autor:	Gregory AE; Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Medical Research and Education Building, Bryan, TX 77807, USA.; Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, Irvine, CA 92617, USA., van Schaik EJ; Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Medical Research and Education Building, Bryan, TX 77807, USA., Fratzke AP; Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Medical Research and Education Building, Bryan, TX 77807, USA., Russell-Lodrigue KE; Tulane University, School of Medicine, Tulane National Primate Research Center, Covington, LA 70433, USA., Farris CM; Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Medical Research and Education Building, Bryan, TX 77807, USA., Samuel JE; Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M University, Medical Research and Education Building, Bryan, TX 77807, USA.
Jazyk:	angličtina
Zdroj:	Cell reports. Medicine [Cell Rep Med] 2021 Dec 06; Vol. 2 (12), pp. 100461. Date of Electronic Publication: 2021 Dec 06 (Print Publication: 2021).
DOI:	10.1016/j.xcrm.2021.100461
Abstrakt:	Q fever is caused by the intracellular bacterium Coxiella burnetii , for which there is no approved vaccine in the United States. A formalin-inactivated whole-cell vaccine (WCV) from virulent C. burnetii NMI provides single-dose long-lived protection, but concerns remain over vaccine reactogenicity. We therefore sought an alternate approach by purifying native C. burnetii antigens from the clonally derived avirulent NMII strain. A soluble bacterial extract, termed Sol II, elicits high-titer, high-avidity antibodies and induces a CD4 T cell response that confers protection in naive mice. In addition, Sol II protects against pulmonary C. burnetii challenge in three animal models without inducing hypersensitivity. An NMI-derived extract, Sol I, enhances protection further and outperforms the WCV gold standard. Collectively, these data represent a promising approach to design highly effective, non-reactogenic Q fever vaccines. Competing Interests: J.E.S., E.J.V.S., and A.E.G. are named inventors of patent US 2019/0083598 A1. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu